Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation)

Area of Science:

• Neurology
• Cardiology
• Pharmacogenomics

Background:

• Transient ischemic attack (TIA) management is evolving with new definitions and risk stratification.
• Guidelines now favor antiplatelet agents over oral anticoagulation for preventing non-cardioembolic stroke.
• Emerging antiplatelet therapies and their impact on cerebrovascular disease require further investigation.

Purpose of the Study:

• To review current understanding and ongoing research in TIA and stroke prevention.
• To highlight the shift towards antiplatelet therapy in clinical guidelines.
• To discuss the potential influence of pharmacogenomics, specifically CYP2C19 polymorphisms, on treatment strategies.

Main Methods:

• Review of recent clinical guidelines and ongoing clinical trials.
• Discussion of emerging antiplatelet drug classes and their application in cerebrovascular disease.
• Exploration of the role of genetic variations in drug response.

Main Results:

• New guidelines recommend antiplatelet agents for stroke/TIA prevention, moving away from oral anticoagulation.
• Clinical trials investigating dual antiplatelet therapy (clopidogrel plus aspirin) for lacunar strokes and acute TIAs are pending.
• The CLOSURE I trial found no significant difference in stroke or TIA rates at 2 years with patent foramen ovale device closure.

Conclusions:

• Current evidence supports antiplatelet therapy as a primary strategy for non-cardioembolic stroke and TIA prevention.
• Future research will likely focus on personalized medicine approaches, including genetic profiling (CYP2C19), to optimize antithrombotic treatment.
• Device closure for patent foramen ovale did not demonstrate superiority over medical management in preventing recurrent stroke or TIA in the study population.